Nordea Investment Management AB increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,003 shares of the medical instruments supplier’s stock after purchasing an additional 123 shares during the period. Nordea Investment Management AB’s holdings in Becton, Dickinson and were worth $1,952,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Almanack Investment Partners LLC. acquired a new position in shares of Becton, Dickinson and during the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust raised its position in shares of Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY raised its position in shares of Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 60 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the last quarter. Finally, Harfst & Associates Inc. raised its position in shares of Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the last quarter. Hedge funds and other institutional investors own 87.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Nordea Investment Management AB Raises Position in Becton, Dickinson and Company (BDX)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/18/nordea-investment-management-ab-raises-position-in-becton-dickinson-and-company-bdx.html.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares in the company, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) opened at 203.07 on Wednesday. The stock has a market capitalization of $46.21 billion, a PE ratio of 58.81 and a beta of 1.05. The firm has a 50-day moving average of $197.13 and a 200 day moving average of $193.13. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.35 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were paid a $0.73 dividend. The ex-dividend date was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.44%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Several research analysts recently issued reports on the company. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Cowen and Company restated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC restated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.